Abstract: A method of estimating stroke volume of the heart is described. In this method, the volume of the heart is estimated from electrical impedance data of the chest, at two different phases of the cardiac cycle. The stroke volume is estimated from the difference between the volumes estimated at the two phases.

Abstract: An electrical energy storage device (20,70) includes a substrate (22), which is formed so as to define a multiplicity of micro-containers separated by electrically-insulating and ion-conducting walls (32). A first plurality of anodes (A) is disposed in a first subset (24) of the micro-containers, and a second plurality of cathodes (C) is disposed in a second subset (26) of the micro-containers. The anodes and cathodes are arranged in an interlaced pattern.

Abstract: The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery.

Abstract: A method of estimating stroke volume of the heart is described. In this method, the volume of the heart is estimated from electrical impedance data of the chest, at two different phases of the cardiac cycle. The stroke volume is estimated from the difference between the volumes estimated at the two phases.

Abstract: Novel compounds designed to allow interactions with binding sites of GSK-3 and hence are capable of inhibiting GSK-3 activity, via inhibition of substrate binding are disclosed. Further disclosed are pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions.

Abstract: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.

Abstract: The present invention provides a cathode and a fuel cell, which are built to prevent escape of liquids, e.g. water and fuel solution, from the cell. Thus, according to a first aspect thereof, the present invention provides a cathode suitable for use in a fuel cell having a proton conducting membrane, the cathode comprising a plurality of layers including a catalyst layer and a hydrophobic porous support layer, wherein at least one of said plurality of layers is a liquid water leak-proof layer, which allows gas to pass through it and prevents passage of liquid water and/or aqueous fuel solution.

Abstract: A method of determining an impedance of at least one lung of a patient having an implanted pacemaker that comprises first and second leads and a case, the method comprising: a) using the leads and the case to acquire at least a first and a second impedance measurement responsive to impedance of the patient's chest that are at least partially independent; and b) using the impedance measurements to determine the impedance of at least one of the lungs substantially independently of impedance of the other lung.

Abstract: Novel conjugates that are capable of inhibiting GSK-3 activity, a process of producing same, pharmaceutical compositions including same and methods of using same in the treatment of GSK-3 mediated conditions are disclosed. Methods of treating affective disorders using GSK-3 inhibitors are further disclosed.

Abstract: The present invention provides a cathode and a fuel cell, which are built to prevent escape of liquids, e.g. water and fuel solution, from the cell. Thus, according to a first aspect thereof, the present invention provides a cathode suitable for use in a fuel cell having a proton conducting membrane, the cathode comprising a plurality of layers including a catalyst layer and a hydrophobic porous support layer, wherein at least one of said plurality of layers is a liquid water leak-proof layer, which allows gas to pass through it and prevents passage of liquid water and/or aqueous fuel solution.

Abstract: Indole derivatives, compositions including same, and methods utilizing same for the treatment of amyloid associated diseases, such as type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis, and prion-related encephalopathies are provided.

Abstract: Light-emitting intra-cavity interferometric (ICI) optical sensors based on channel waveguide structures which include an internal light emitting material and a functionalized region. In some embodiments, the waveguides are made of a sol-gel which incorporates the light emitting material. In some embodiments, the waveguide structure includes an ICI resonator backbone and the ICI sensor is a laser sensor. In some embodiments, the resonator backbone has an interferometric Y-branch shape. In some embodiments, the resonator backbone has a Mach Zehnder interferometer shape. In some embodiments, an ICI laser sensor has an interferometric arrayed waveguide grating shape. In some embodiments, an ICI sensor may be remotely optically pumped and remotely read.

Abstract: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.

Abstract: Indole derivatives, compositions including same, and methods utilizing same for the treatment of amyloid associated diseases, such as type II diabetes mellitus, Alzheimer's dementia or diseases, systemic and localized amyloidosis, and prion-related encephalopathies are provided.

Abstract: The present invention provides a cathode and a fuel cell, which are built to prevent escape of liquids, e.g. water and fuel solution, from the cell. Thus, according to a first aspect thereof, the present invention provides a cathode suitable for use in a fuel cell having a proton conducting membrane, the cathode comprising a plurality of layers including a catalyst layer and a hydrophobic porous support layer, wherein at least one of said plurality of layers is a liquid water leak-proof layer, which allows gas to pass through it and prevents passage of liquid water and/or aqueous fuel solution.

Abstract: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X-Y or Y-X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.

Abstract: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X—Y or Y—X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such peptides as well as methods using same for diagnosing and treating amyloid associated diseases.

Abstract: An electrical energy storage device includes a substrate having an outer surface and having a plurality of cavities communicating with the outer surface. The cavities have interior cavity surfaces. A first electrode layer is deposited at least over the interior cavity surfaces. An electrolyte separator layer is formed over the first electrode layer so as to fill the cavities and to extend over the outer surface of the planar substrate. A second electrode layer is formed over the electrolyte separator layer on the outer surface of the planar substrate.

Abstract: A peptide comprising at least 5 amino acid residues and less than 15 amino acid residues, the peptide including an amino acid sequence as set forth in SEQ ID NO: 7 as well as pharmaceutical compositions, kits and methods for diagnosing and treating amyloid associated diseases.

Abstract: Lipidated glycosaminoglycan particles are prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaiminoglycan with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs for use in the treatment of pathological conditions in an animal.